描述

The global prostate cancer drug market in terms of revenue is set to grow by US$ 11 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 10.5% 在预测期内, 据数据和分析公司 StrategyHelix 称.

该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for prostate cancer drug. The global prostate cancer drug market is segmented on the basis of type. 按类型, it is categorized into Abiraterone acetate, Enzalutamide, Goserelin, and Leuprorelin.

The report has profiled some of the key players of the market such as Pfizer Inc., Beijing Biote Pharmaceutical Co. 有限公司, 约翰逊 & Johnson International Inc., Livzon Pharmaceutical Group Inc., Takeda Pharmaceutical Co. 有限公司.

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the prostate cancer drug market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

类型: Abiraterone acetate, Enzalutamide, Goserelin, and Leuprorelin
考虑年数: 本报告涵盖期间 2017 到 2027

利益相关者的主要好处

Get a comprehensive picture of the global prostate cancer drug market
精准定位增长领域和投资趋势
Understand what the future of the global prostate cancer drug market looks like
确定竞争格局和机会之窗

目录

1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Prostate Cancer Drug Market by Type
4.1 Abiraterone Acetate
4.2 Enzalutamide
4.3 Goserelin
4.4 Leuprorelin
5. 公司简介
5.1 Pfizer, 公司.
5.2 Beijing Biote Pharmaceutical Co., 有限公司.
5.3 约翰逊 & Johnson International, 公司.
5.4 Livzon Pharmaceutical Group Inc.
5.5 Takeda Pharmaceutical Co. 有限公司.
6. 附录
6.1 关于StrategyHelix
6.2 免责声明